Cargando…

Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways

Dysregulation of MDM2, a p53 negative regulator, frequently occurs in acute myeloid leukemia (AML) and is associated with unfavorable prognoses, rendering the p53-MDM2 axis an attractive target for the development of small-molecule inhibitors. MDM2 antagonists have been intensely developed but only...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qinwei, Deng, Suqi, Deng, Manman, Shi, Yuanfei, Zhong, Mengya, Ding, Lihong, Jiang, Yuelong, Zhou, Yong, Carter, Bing Z., Xu, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013083/ https://www.ncbi.nlm.nih.gov/pubmed/35429966 http://dx.doi.org/10.1186/s40164-022-00276-z

Ejemplares similares

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
por: Zhong, Mengya, et al.
Publicado: (2021)

Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
por: Shi, Yuan-Fei, et al.
Publicado: (2020)

Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells
por: Li, Yin, et al.
Publicado: (2017)

Low frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia
por: Yan, Bowen, et al.
Publicado: (2020)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption
por: Zhao, Haijun, et al.
Publicado: (2016)

Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway
por: Chen, Qiuling, et al.
Publicado: (2022)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Triptolide interrupts rRNA synthesis and induces the RPL23-MDM2-p53 pathway to repress lung cancer cells
por: Wang, Juan, et al.
Publicado: (2020)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34(+) proliferating and quiescent chronic myeloid leukemia blast crisis cells
por: Carter, Bing Z., et al.
Publicado: (2015)

Triptolide Shows High Sensitivity and Low Toxicity Against Acute Myeloid Leukemia Cell Lines Through Inhibiting WSTF-RNAPII Complex
por: Kang, Di, et al.
Publicado: (2022)

Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia
por: Deng, Manman, et al.
Publicado: (2018)

Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities
por: Huang, Yijun, et al.
Publicado: (2014)

Mdmx promotes genomic instability independent of p53 and Mdm2
por: Carrillo, Alexia M., et al.
Publicado: (2014)

Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
por: Carter, Bing Z., et al.
Publicado: (2020)

SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients
por: Liu, Fangshu, et al.
Publicado: (2023)

Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
por: Ye, Jing, et al.
Publicado: (2019)

Casein kinase 1α inhibits p53 downstream of MDM2-mediated autophagy and apoptosis in acute myeloid leukemia
por: Xu, Wanling, et al.
Publicado: (2020)

MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation
por: Qi, Dong-Lai, et al.
Publicado: (2016)

Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways
por: Li, Genhong, et al.
Publicado: (2023)

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
por: Azmi, Asfar S., et al.
Publicado: (2011)

The MDM2/MDMX/p53 axis in the adaptive stress response
por: Wang, Bing, et al.
Publicado: (2020)

Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Guo, Yong, et al.
Publicado: (2022)

Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang
por: Zhou, Hong-Sheng, et al.
Publicado: (2016)

Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1
por: Ding, Xiwei, et al.
Publicado: (2014)

Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells
por: Lama, Rati, et al.
Publicado: (2022)

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2018)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
por: Jiang, Liren, et al.
Publicado: (2019)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells
por: Wu, W, et al.
Publicado: (2015)

Development and optimization of sustained release triptolide microspheres
por: Zeng, Hui-lin, et al.
Publicado: (2023)

Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
por: Uy, Geoffrey L., et al.
Publicado: (2020)

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
por: Lehmann, Christian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ilg5494hjbjaukccqokdmt6mjh